Comparison · NCT02727699-sae
Xanamem™ vs Placebo: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Xanamem™ vs Placebo: serious adverse events. Trial comparisons, record NCT02727699-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02727699-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.044 | 0.0172 | 0.108 | wilson | |
| Risk in group 2 | 0.0426 | 0.0167 | 0.104 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0014 | -0.0659 | 0.0701 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.03 | 0.266 | 4.01 | log | |
| Odds ratio, group 1 over group 2 | 1.03 | 0.251 | 4.27 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Xanamem™ than on Placebo | 713 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Xanamem™ | Oral Xanamem™ capsules 10mg, to be administered once daily~Xanamem™: Xanamem™ is formulated in green and cream coloured size 3, Coni-Snap shaped gelatin capsules as an excipient blend at a dose of 10mg. It contains active pharmaceutical ingredient of UE2343 | 4 | 91 | EG000 |
| Group 2 | Placebo | Matching placebo which is identical in appearance to the test product except that it contains no active ingredient, to be administered once daily~Placebo (for Xanamem™): Excipient blend capsules manufactured to mimic Xanamem™ capsules | 4 | 94 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Median treatment duration (weeks) was 12 weeks (range: 0.14, 13.0 weeks) for subjects in the Xanamem group and 12 weeks (range: 0.14, 13.1 weeks) for subjects in the placebo group.
Source ClinicalTrials.gov
Trial
- Title
- A Phase II Study to Assess the Safety, Tolerability and Efficacy of Xanamem™ in Subjects With Mild Dementia Due to AD (XanADu)
- NCT number
- NCT02727699
- Phases
- PHASE2
- Conditions
- Dementia, Alzheimer Type
- Interventions
- Xanamem™, Placebo (for Xanamem™)
- Lead sponsor
- Actinogen Medical
- Results first posted
- 2021-05-06
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02727699?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02727699-sae